|
1
|
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
|
Lancet
|
2010
|
13.59
|
|
2
|
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
|
Leukemia
|
2007
|
2.96
|
|
3
|
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
|
Leukemia
|
2004
|
1.68
|
|
4
|
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.
|
Leukemia
|
2012
|
1.60
|
|
5
|
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
|
Leukemia
|
2009
|
1.16
|
|
6
|
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
|
Leukemia
|
2012
|
1.14
|
|
7
|
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.
|
Leukemia
|
2012
|
1.13
|
|
8
|
Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
|
Leukemia
|
2004
|
1.09
|
|
9
|
A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.
|
Leukemia
|
2007
|
1.00
|
|
10
|
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
|
Leukemia
|
2004
|
0.97
|
|
11
|
Blood on filter paper as a readily available source of bcr-abl rearranged mRNA.
|
Blood
|
1997
|
0.87
|
|
12
|
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
|
Leukemia
|
2013
|
0.86
|
|
13
|
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
|
Leukemia
|
2012
|
0.85
|
|
14
|
The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?
|
Leukemia
|
2005
|
0.85
|
|
15
|
Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus.
|
Clin Exp Immunol
|
2006
|
0.81
|
|
16
|
Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML.
|
Bone Marrow Transplant
|
2008
|
0.76
|
|
17
|
Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease.
|
Leukemia
|
2012
|
0.75
|